News Release

HemogloBind™ Used in Study of Sickle Cell Disease

MONMOUTH JUNCTION, NJ, September 14, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interference, in a study investigating sickle cell disease.

The citation is:

Barakat, Amey, et al. "Effects of 2, 3‐DPG knockout on SCD phenotype in Townes SCD model mice." American Journal of Hematology (2023).

Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3-DPG by activation of Pyruvate Kinase-R are currently being evaluated in SCD patients. In this study, a genetically engineered mouse was used to evaluate the effects of 2,3-DPG loss on disease pathology. For Western blot analysis, the article states “Red blood cells were lysed by vortexing and hemoglobin was depleted using HemogloBind™. Sample was separated on a 4%-12% NuPAGE Bis-tris gel…”. The article concludes that animals lacking 2,3-DPG showed improvements in hematological markers and reductions in RBC sickling relative to native Townes mice, however, minimal difference in organ damage was observed in 2,3-DPG deficient mice compared to native Townes animals. When animals lacking 2,3-DPG were dosed with a compound designed to increase hemoglobin oxygen affinity, oxygen delivery related toxicity was observed.

“All of our products are species agnostic, as they not derived from immuno-affinity, so they work for all species. This article is a good example of that, as here HemogloBind™, is used here to clear interference in a Western blot analysis from mouse RBCs.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Silica nanoparticles, Erythrocytotoxicity, Hemoglobin Removal, HemogloBind™, phosphorylated ERK1/2

About Biotech Support Group LLC

Converging with technological disruptions forthcoming in healthcare, Biotech Support Group continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com